PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL
Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)65190-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)65190-X/fulltext
Section Title :
Section Order :
351
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65190-X&doi=10.1016/S1098-3015(10)65190-X